MDGL:NSC-Madrigal Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 258.81

Change

+11.19 (+4.52)%

Market Cap

USD 0.19B

Volume

0.44M

Analyst Target

USD 171.71
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH).

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 102.73B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 96.94B
MRNA Moderna Inc

N/A

USD 38.83B
ARGX argenx NV ADR

N/A

USD 22.16B
BNTX BioNTech SE

N/A

USD 21.93B
GMAB Genmab AS

N/A

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 18.12B
RPRX Royalty Pharma Plc

N/A

USD 16.73B
BGNE BeiGene Ltd

N/A

USD 16.68B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.35B

ETFs Containing MDGL

SURI Simplify Propel Opportuni.. 5.62 % 0.00 %

N/A

USD 0.12B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 0.92B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.85% 60% D- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.85% 60% D- 75% C
Trailing 12 Months  
Capital Gain 8.61% 62% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.61% 61% D- 60% D-
Trailing 5 Years  
Capital Gain 106.62% 84% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 106.62% 84% B 83% B
Average Annual (5 Year Horizon)  
Capital Gain 92.30% 90% A- 95% A
Dividend Return 92.30% 90% A- 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 725.03% 8% B- 3% F
Risk Adjusted Return 12.73% 70% C- 52% F
Market Capitalization 0.19B 96% N/A 89% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 13.02 11% 9%
Price / Cash Flow Ratio -15.81 88% 84%
Price/Free Cash Flow Ratio -13.21 90% 86%
Management Effectiveness  
Return on Equity -123.98% 33% 16%
Return on Invested Capital -99.15% 24% 11%
Return on Assets -47.41% 27% 9%
Debt to Equity Ratio 28.49% 39% 52%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector